BioMarin’s stock falls after another company’s dwarfism drug moves into Phase 3 clinical trials

Shares of BioMarin Pharmaceutical Inc. BMRN were down about 6.0% in premarket trading on Monday after BridgeBio Pharma Inc. BBIO shared positive Phase 2 clinical data about its experimental dwarfism drug, which could compete with BioMarin’s Voxzogo if and when it’s approved. BioMarin received Food and Drug Administration approval for Voxzogo as a treatment for some children 5 years old and older with achondroplasia in late 2021. The drug generated about $169 million in sales last year.

... Shares of BioMarin Pharmaceutical Inc. BMRN were down about 6.0% in premarket trading on Monday after BridgeBio Pharma Inc. BBIO shared positive Phase 2 clinical data about its experimental dwarfism drug, which could compete with BioMarin’s Voxzogo if and when it’s approved. BioMarin received Food and Drug Administration approval for Voxzogo as a treatment for some children 5 years old and older with achondroplasia in late 2021. The drug generated about $169 million in sales last year.

Finance Finance Latest News, Finance Finance Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

BridgeBio’s stock rallies 50% on new data from dwarfism therapyShares of BridgeBio Pharma Inc. soared about 52% in premarket trading on Monday after the company shared positive data from a Phase 2 clinical trial about...
Source: MarketWatch - 🏆 3. / 97 Read more »

AUD/USD: Weak phase over? – UOBIn the opinion of UOB Group’s Economist Lee Sue Ann and Markets Strategist Quek Ser Leang, AUD/USD has now likely moved into a consolidative range. Ke
Source: FXStreetNews - 🏆 14. / 72 Read more »